You are here: Industry Insights > Ridgeback Biotherapeutics

News List

Ridgeback Biotherapeutics’ Ebola treatment scores FDA approval pharmatimes
December 24, 2020
Ridgeback Biotherapeutics’ Ebanga has been approved by the US Food and Drug Administration (FDA) for the treatment of Ebola in adult and paediatric patients.
Merck joins race to develop Covid-19 vaccines and drugs pharmaceutical-technology
May 27, 2020
Merck (MSD) has joined the race to develop vaccines and treatments against Covid-19 with separate agreements with Themis, IAVI and Ridgeback Biotherapeutics.
Ridgeback Biotherapeutics announces MHRA clearance to begin human testing of EIDD-2801 in UK for COVID-19 pharmaceutical-business-review
April 16, 2020
Ridgeback Biotherapeutics announced clearance by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
FDA authorises Emory University to trial antiviral for Covid-19 pharmaceutical-technology
April 09, 2020
Emory University subsidiary DRIVE has received the US Food and Drug Administration (FDA) approval for its investigational new drug application of antiviral compound EIDD-2801 to treat Covid-19.
Ridgeback Biotherapeutics and DRIVE to develop Covid-19 drug pharmaceutical-technology
March 23, 2020
Ridgeback Biotherapeutics and Emory University’s not-for-profit Drug Innovations at Emory (DRIVE) have partnered to develop a drug candidate for potential treatment of Covid-19.